Pages that link to "Q44666547"
The following pages link to Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques (Q44666547):
Displaying 50 items.
- T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance (Q28083810) (← links)
- Anticalins: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies (Q30157932) (← links)
- Anticalins as an alternative to antibody technology (Q30160091) (← links)
- Ipilimumab: from preclinical development to future clinical perspectives in melanoma (Q30240751) (← links)
- The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: study design, data analysis, interpretation (Q30764037) (← links)
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy (Q34149569) (← links)
- Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria (Q34492813) (← links)
- Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 (Q34567635) (← links)
- Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism (Q35029947) (← links)
- CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques (Q35848881) (← links)
- Inhibitory receptors as targets for cancer immunotherapy (Q35995373) (← links)
- Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology (Q36127709) (← links)
- Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells. (Q36140846) (← links)
- Human antibodies from transgenic animals (Q36252986) (← links)
- Principles and use of anti-CTLA4 antibody in human cancer immunotherapy (Q36389992) (← links)
- Checkpoint blockade in cancer immunotherapy (Q36490768) (← links)
- Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer (Q36589870) (← links)
- Immunostimulatory monoclonal antibodies for cancer therapy (Q36717901) (← links)
- Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma (Q36879912) (← links)
- Update on anti-CTLA-4 antibodies in clinical trials (Q36909389) (← links)
- Enhancing cancer vaccines with immunomodulators (Q36960748) (← links)
- The role of the CTLA4 blockade in the treatment of malignant melanoma (Q37008621) (← links)
- Human monoclonal antibodies from transgenic mice (Q37028982) (← links)
- Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management (Q37131014) (← links)
- T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy (Q37157984) (← links)
- An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. (Q37208517) (← links)
- CTLA4 blockade increases Th17 cells in patients with metastatic melanoma (Q37229358) (← links)
- Anti-CTLA4 Antibody Clinical Trials in Melanoma (Q37234763) (← links)
- Systemic cancer therapy: evolution over the last 60 years (Q37271928) (← links)
- Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. (Q37400623) (← links)
- Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma (Q37542216) (← links)
- Profile of ipilimumab and its role in the treatment of metastatic melanoma (Q37977920) (← links)
- The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma (Q37985890) (← links)
- Unmasking the immune recognition of prostate cancer with CTLA4 blockade (Q37989393) (← links)
- Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management (Q38166382) (← links)
- Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade (Q38577834) (← links)
- Combination cancer immunotherapies tailored to the tumour microenvironment (Q38645178) (← links)
- Immune checkpoint inhibitors for cancer treatment. (Q38988058) (← links)
- A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet (Q39066797) (← links)
- Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. (Q39108760) (← links)
- The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production (Q39157852) (← links)
- CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells (Q40266751) (← links)
- Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award (Q43218579) (← links)
- Ipilimumab for the treatment of metastatic prostate cancer (Q47225399) (← links)
- Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies (Q50125936) (← links)
- A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. (Q52689094) (← links)
- Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. (Q53428689) (← links)
- Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade? (Q54224259) (← links)
- Immune consequences of anti-angiogenic therapyin renal cell carcinoma. (Q54981236) (← links)
- A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions. (Q55336684) (← links)